Last week, CIRM’s governing Board approved funding for a Phase 3 clinical trial testing a stem cell-based treatment that could eliminate the need for immunosuppressive drugs in some patients receiving kidney transplants. Over 650,000 Americans suffer from end-stage kidney disease - a life-threatening condition caused by the loss of kidney function. The best available treatment … Continue reading CIRM Invests in Medeor Therapeutics’ Phase 3 Clinical Trial to Help Kidney Transplant Patients
Clinical Trials
A year in review – CIRM’s 2017 Annual Report focuses on a year of accelerating stem cell treatments to patients
At CIRM we have our focus very clearly on the future, on accelerating stem cell therapies to patients with unmet medical needs. But every once in a while, it’s a good idea to look back at what you have already done. Knowing where you came from can help you get to where you are heading. … Continue reading A year in review – CIRM’s 2017 Annual Report focuses on a year of accelerating stem cell treatments to patients
Taking a new approach to fighting a deadly brain cancer
CIRM’s 2017 Annual Report will be going live online very soon. In anticipation of that we are highlighting some of the key elements from the report here on the Stem Cellar. One of the most exciting new approaches in targeting deadly cancers is chimeric antigen receptor (CAR) T-cell therapy, using the patient’s own immune system … Continue reading Taking a new approach to fighting a deadly brain cancer
Stem Cell RoundUp: CIRM Clinical Trial Updates & Mapping Human Brain
It was a very CIRMy news week on both the clinical trial and discovery research fronts. Here are some the highlights: Stanford cancer-fighting spinout to Genentech: 'Don't eat me' – San Francisco Business Times Ron Leuty, of the San Francisco Business Times, reported this week on not one, but two news releases from CIRM grantee … Continue reading Stem Cell RoundUp: CIRM Clinical Trial Updates & Mapping Human Brain
Recap of the 2018 Alliance for Regenerative Medicine Cell and Gene Therapy State of the Industry
What happened in the Cell and Gene Therapy sector in 2017, and what should we be looking out for in 2018? Over 500 executives, investors, scientists and patient advocates gathered together yesterday to find out at the Alliance for Regenerative Medicine (ARM) State of the Industry Briefing in San Francisco, California. ARM Chairman, Robert Preti, … Continue reading Recap of the 2018 Alliance for Regenerative Medicine Cell and Gene Therapy State of the Industry
Stem Cell Roundup: Gene therapy for diabetes, alcohol is bad for your stem cells and hairy skin
The start of a new year is the perfect opportunity to turn a new leaf. I myself have embraced 2018 with open arms and decided to join my fellow millennials who live and die by the acronym YOLO. How am I doing this? Well, so far, I got a new haircut, I started doing squats … Continue reading Stem Cell Roundup: Gene therapy for diabetes, alcohol is bad for your stem cells and hairy skin
How Tom Howing turned to stem cells to battle back against a deadly cancer
As we enter the new year, CIRM’s 2017 Annual Report will be posted in less than two weeks! Here’s one of the people we are profiling in the report, a patient who took part in a CIRM-funded clinical trial. In March of 2015, Tom Howing was diagnosed with stage 4 cancer. Over the next 18 … Continue reading How Tom Howing turned to stem cells to battle back against a deadly cancer
Accelerating stem cell treatments to patients in 2017
As we enter the new year, CIRM’s 2017 Annual Report will be posted in a few short weeks! Here’s a sneak peek at CIRM’s progress in clinical trials. At the start of 2017, we set a goal of finding and funding 12 new, high quality clinical trials. We easily beat that goal, funding 16, in … Continue reading Accelerating stem cell treatments to patients in 2017
Budgeting for the future of the stem cell agency
Budgets are very rarely exciting things; but they are important. For example, it’s useful for a family to know when they go shopping exactly how much money they have so they know how much they can afford to spend. Stem cell agencies face the same constraints; you can’t spend more than you have. Last week … Continue reading Budgeting for the future of the stem cell agency
jCyte Shares Encouraging Update on Clinical Trial for Retinitis Pigmentosa
Stepping out of the darkness into light. That’s how patients are describing their experience after participating in a CIRM-funded clinical trial targeting a rare form of vision loss called retinitis pigmentosa (RP). jCyte, the company conducting the trial, announced 12 month results for its candidate stem cell-based treatment for RP. RP is a genetic disorder … Continue reading jCyte Shares Encouraging Update on Clinical Trial for Retinitis Pigmentosa
The Stem Cellar 